As a leading innovator of precision radiation therapy solutions, Elekta is committed to ensuring that every patient has access to the best cancer care possible.

From vision to reality

We’ve been working openly and proactively with clinicians and our partners for almost half a century to develop sustainable, outcome-driven and cost-efficient solutions that meet evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4700 employees combine passion, science, and imagination to profoundly change cancer care and bring hope to everyone dealing with cancer.

Prof Lars Leksell
“Today’s shortage in radiotherapy equipment is unacceptable. We have a responsibility to change this and will do our part by delivering new, innovative solutions for cancer care.”
Gustaf Salford, President and CEO

Pioneer in Precision Radiation Therapy

Pioneer in Precision Radiation Medicine
24-million

Our strategy

We want to do our part to move towards a world where everyone has access to the best cancer care. With our strategy ACCESS 2025, we set the focus on closing the access gap, elevating cancer care and increasing the patients’ participation in their own care. One key target is that an additional +300 million people in underserved communities will gain access to radiation therapy around the world.

Boy and teacher

Everyone deserves high-quality care

Innovative solutions

Elekta is pushing the boundaries of radiation therapy to create solutions that provide a lasting clinical difference. We don't just build technology, we build hope.

Radiotherapy
Stereotactic Radiosurgery
 
MR/RT
Oncology Informatics
 
Neurosurgery
Brachytherapy

Find out more about our headquarters and global locations, the management team, career opportunities, sustainability initiatives and investor relations on elekta.com. Click here to contact us directly.

  1. WHO Report on cancer, available at https://www.who.int/publications/i/item/who-report-on-cancer-setting-priorities-investing-wisely-and-providing-care-for-all (excl. non-melanoma skin cancer).
  2.  Ferlay J, et al. Global Cancer Observatory: Cancer Tomorrow. Lyon: International Agency for Research on Cancer, 2020; UN World Population Prospects 2019; International Atomic Energy Agency: DIRAC (Directory of Radiotherapy Centres), 2021
  3. Atun et al, Expanding global access to radiotherapy, The Lancet Oncol 2015 Sep; 16(10): 1153-86 https://pubmed.ncbi.nlm.nih.gov/26419354/ .
  4.  Lievens Y, et al. Radiother and Oncol 2017;125:175-177.
  5.  Atun R, et al. Lancet Oncol Commission 2015; 16(10): 1153-1186. Date of preparation: September 2018.